Literature DB >> 17172071

Successful bone marrow transplantation in an 8-month-old patient with chronic granulomatous disease.

Savaş Kansoy1, Necil Kütükçüler, Serap Aksoylar, Güzide Aksu, Mehmet Kantar, Nazan Cetingül.   

Abstract

An eight-month-old boy with chronic granulomatous disease (CGD) received HLA identical sibling bone marrow transplantation (BMT) following busulphan and cyclophosphamide conditioning. No graft-versus-host disease was demonstrated. Five years after transplantation, mixed chimerism was 60% in peripheral blood, and 85% of his neutrophils had normal oxidative burst activity. He is now six years old, in very good health and growing well. In this period, he experienced no severe infectious diseases. To our knowledge, this is the first case of CGD who had BMT in Turkey. His successful outcome illustrates that BMT in a patient with CGD in the first years of life should be considered early if an HLA-matched donor is already available, before development of any recurrent life-threatening infections or irreversible organ damage.

Entities:  

Mesh:

Year:  2006        PMID: 17172071

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  3 in total

Review 1.  Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.

Authors:  Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

2.  Advances in treatment for chronic granulomatous disease.

Authors:  Elizabeth M Kang; Harry L Malech
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

3.  Bone marrow aplasia following donor lymphocyte infusion in 4-year-old patient with chronic granulomatous disease after allogeneic stem cell transplantation: case report.

Authors:  Magdalena Cienkusz; Monika Lejman; Nel DĄbrowska-Leonik; Marta Choma; Katarzyna Drabko
Journal:  Cent Eur J Immunol       Date:  2020-09-24       Impact factor: 2.085

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.